Peptide Therapy Scottsdale
Physician-prescribed GLP-1 agonists and growth hormone peptides offer the most powerful pharmacological tools available for medically supervised fat loss. We combine semaglutide, tirzepatide, AOD-9604, and CJC-1295/Ipamorelin in protocols customized to your biology.
The Science
Peptides are short chains of amino acids — the building blocks of proteins — that act as biological messengers in the body. Certain peptides have potent, targeted effects on fat metabolism, appetite regulation, insulin sensitivity, and growth hormone secretion.
Unlike broad-spectrum medications, peptides work through highly specific receptor pathways. GLP-1 agonists like semaglutide and tirzepatide mimic naturally occurring gut hormones to reduce appetite and improve metabolic efficiency. Growth hormone secretagogues like CJC-1295/Ipamorelin stimulate the pituitary gland to release growth hormone, which drives lipolysis and lean mass preservation.
These aren't experimental fringe treatments. GLP-1 receptor agonists are FDA-approved drugs with robust clinical trial data. Peptide therapies like CJC-1295/Ipamorelin and AOD-9604 have strong safety profiles and are prescribed by physicians at longevity and metabolic health clinics across the country.
Activate gut-brain signaling to reduce hunger, slow gastric emptying, improve insulin secretion, and lower blood glucose — producing significant, sustained weight loss.
Stimulate the pituitary to release growth hormone in a physiologic pulse pattern — driving fat mobilization, lean mass preservation, and improved sleep quality.
A modified fragment of growth hormone that selectively stimulates fat breakdown and inhibits fat storage — without the IGF-1 elevation or glucose effects of full hGH.
GLP-1 Agonists
The most clinically validated weight loss medications available. Physician-prescribed and monitored at every step.
GLP-1 Receptor Agonist
Semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity) is a once-weekly injectable GLP-1 receptor agonist. It binds to GLP-1 receptors in the brain's hypothalamus — reducing appetite and food cravings — while also slowing gastric emptying and improving insulin secretion.
The landmark STEP trials demonstrated 14.9–17.4% average body weight reduction at 68 weeks in adults with obesity. Patients also showed significant improvements in cardiovascular risk markers, blood pressure, and blood glucose levels.
Dual GLP-1/GIP Receptor Agonist
Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) activates both GLP-1 and GIP receptors simultaneously. This dual mechanism produces markedly superior weight loss compared to GLP-1 monotherapy — and represents the current cutting edge of obesity pharmacotherapy.
The SURMOUNT-1 trial showed average weight loss of 20.9% at the highest dose over 72 weeks, with 57% of participants losing more than 20% of body weight. It also produces significant improvements in triglycerides, insulin resistance, and non-alcoholic fatty liver disease.
Growth Hormone Peptides
Targeted peptides that stimulate natural fat metabolism and growth hormone release — without the side effects of synthetic hGH.
AOD-9604 (Anti-Obesity Drug 9604) is a stabilized analogue of the C-terminal fragment of human growth hormone, specifically the amino acid sequence 176–191. It directly stimulates lipolysis (fat breakdown) and inhibits lipogenesis (new fat cell creation) — without activating IGF-1 or altering blood glucose levels.
CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) with an extended half-life. It signals the pituitary gland to produce and release more growth hormone over a sustained period, increasing average daily GH output by 2–10x baseline — which drives fat mobilization, muscle preservation, and accelerated recovery.
Ipamorelin is a selective ghrelin receptor agonist (growth hormone secretagogue) that triggers a clean, pulsatile release of growth hormone from the pituitary — without significantly elevating cortisol, prolactin, or appetite. Typically combined with CJC-1295 to create a synergistic GHRH + GHRP protocol with superior GH output.
Choosing Your Protocol
Your physician will recommend a protocol based on your weight loss goals, current medications, medical history, and lab results.
| Protocol | Best For | Mechanism | Frequency | Typical Results |
|---|---|---|---|---|
| Semaglutide | Significant weight loss, blood sugar control | GLP-1 agonist — appetite & insulin | 1x/week injection | ~15% BW reduction |
| Tirzepatide | Maximum weight loss, insulin resistance | Dual GLP-1/GIP agonist | 1x/week injection | ~22% BW reduction |
| CJC-1295 / Ipamorelin | Body recomposition, anti-aging, recovery | GH secretagogue — lipolysis & LBM | Daily injection (pre-sleep) | Fat loss + muscle gain |
| AOD-9604 | Stubborn fat, metabolic enhancement | hGH fragment — direct lipolysis | Daily injection | Targeted fat reduction |
| Combination Stack | Maximum results, complex cases | Multi-pathway synergistic approach | Varies by protocol | Optimal outcomes |
Common Questions
Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and improve insulin sensitivity. Tirzepatide is a dual GLP-1/GIP receptor agonist — activating both pathways simultaneously for greater weight loss efficacy. Clinical trials show tirzepatide achieves up to 22.5% body weight reduction vs. 15–17% for semaglutide at equivalent timepoints.
AOD-9604 is a modified fragment of human growth hormone (hGH) designed specifically to target fat metabolism. Unlike full hGH, AOD-9604 does not raise IGF-1 or affect blood glucose. It directly stimulates lipolysis (fat breakdown) and inhibits lipogenesis (new fat storage), making it particularly effective for stubborn fat deposits, especially visceral and abdominal fat.
Yes. Many patients benefit from combining GLP-1 agonists with growth hormone secretagogue peptides like CJC-1295/Ipamorelin. The combination addresses both appetite regulation and metabolic rate, often producing results superior to either therapy alone. Your physician will design a stack based on your specific goals, current medications, and lab results.
When prescribed and monitored by a physician, weight loss peptides and GLP-1 agonists have well-established safety profiles. Side effects are typically mild and transient — nausea with GLP-1s during dose escalation, temporary mild redness at injection sites with peptides. We monitor all patients with baseline and follow-up labs throughout treatment, with dose adjustments as needed.
Most weight loss peptide programs run for a minimum of 3–6 months to assess full efficacy. GLP-1 agonists may be continued long-term for sustained weight maintenance — similar to how antihypertensives are used chronically for blood pressure control. Your physician will determine the optimal duration and transition plan based on your goals and response to treatment.
Your free consultation includes a full discussion of peptide options, candidacy assessment, and a clear protocol recommendation — tailored to your body and goals.